BIIB Biogen Inc

Price (delayed)

$220.99

Market cap

$32.07B

P/E Ratio

15.74

Dividend/share

N/A

EPS

$14.04

Enterprise value

$36.97B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
The EPS has grown by 43% from the previous quarter and by 10% YoY
Biogen's net income has increased by 42% QoQ and by 7% YoY
The gross profit is down by 16% year-on-year and by 2.5% since the previous quarter
The company's quick ratio fell by 12% YoY and by 7% QoQ

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
145.11M
Market cap
$32.07B
Enterprise value
$36.97B
Valuations
Price to earnings (P/E)
15.74
Price to book (P/B)
2.73
Price to sales (P/S)
3.03
EV/EBIT
13.12
EV/EBITDA
10.85
EV/Sales
3.48
Earnings
Revenue
$10.63B
EBIT
$2.82B
EBITDA
$3.41B
Free cash flow
$2.33B
Per share
EPS
$14.04
Free cash flow per share
$15.99
Book value per share
$81.07
Revenue per share
$72.88
TBVPS
$118.28
Balance sheet
Total assets
$25.08B
Total liabilities
$13.22B
Debt
$7.55B
Equity
$11.87B
Working capital
$4.72B
Liquidity
Debt to equity
0.64
Current ratio
1.94
Quick ratio
1.36
Net debt/EBITDA
1.44
Margins
EBITDA margin
32%
Gross margin
77.3%
Net margin
19.4%
Operating margin
30.7%
Efficiency
Return on assets
8.5%
Return on equity
18.5%
Return on invested capital
16.3%
Return on capital employed
14%
Return on sales
26.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
1.27%
1 week
1.28%
1 month
2.51%
1 year
-35.13%
YTD
-7.89%
QTD
8.36%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$10.63B
Gross profit
$8.22B
Operating income
$3.26B
Net income
$2.06B
Gross margin
77.3%
Net margin
19.4%
Biogen's operating margin has soared by 55% YoY and by 29% from the previous quarter
Biogen's net margin has increased by 45% from the previous quarter and by 18% YoY
Biogen's net income has increased by 42% QoQ and by 7% YoY
BIIB's operating income is up by 41% year-on-year and by 27% since the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
15.74
P/B
2.73
P/S
3.03
EV/EBIT
13.12
EV/EBITDA
10.85
EV/Sales
3.48
The EPS has grown by 43% from the previous quarter and by 10% YoY
The P/E is 27% below the last 4 quarters average of 21.5 and 2.8% below the 5-year quarterly average of 16.2
BIIB's price to book (P/B) is 32% lower than its 5-year quarterly average of 4.0 and 12% lower than its last 4 quarters average of 3.1
The equity has grown by 10% YoY and by 6% from the previous quarter
The stock's price to sales (P/S) is 22% less than its 5-year quarterly average of 3.9 and 5% less than its last 4 quarters average of 3.2
Biogen's revenue has decreased by 9% YoY

Efficiency

How efficient is Biogen business performance
The ROIC has soared by 83% from the previous quarter and by 66% YoY
The ROS has soared by 82% from the previous quarter and by 71% YoY
Biogen's return on assets has increased by 39% QoQ and by 9% YoY
The ROE has grown by 38% from the previous quarter and by 3.4% YoY

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 90% more than the total liabilities
The company's quick ratio fell by 12% YoY and by 7% QoQ
The current ratio has contracted by 10% YoY and by 3.5% from the previous quarter
Biogen's debt is 36% less than its equity
The debt to equity has decreased by 10% YoY and by 4.5% from the previous quarter
The equity has grown by 10% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.